About the Journal
FOCUS & SCOPE
The Journal of Applied Pharmaceutical Research (JOAPR) is an official publication of Creative Pharma Assent (CPA). It is an open access, peer review online international journal. JOAPR is primarily focused on multiple discipline of pharmaceutical sciences (Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Cosmetic Technology, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Herbal drugs/ formulations, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest) which publish quarterly. JOAPR also includes evaluation of pharmaceutical excipients & their practical application to research & industry based efforts. The aim of the scientific journal, JOAPR is to present a wide area for the current researchers to share their noble works and ideas in terms of the research papers, review articles and short communications. JOAPR only publish the original research works with a definite innovation and novelty after thorough reviewing. The paper must have a suitable and proper scientific background.
We believe in fast review and publication of manuscript.
We are committed to prompt evaluation and publication of fully accepted papers in journals. To maintain a high-quality publication, all submissions undergo a rigorous review process. Characteristics of the peer review process are as follows:
- Simultaneous submissions of the same manuscript to different journals is not acceptable
- Papers will be refereed by experts as suggested by the editorial board.
- All publication decisions are made by the journal's Editors-in-Chief on the basis of the referees' reports. Authors of papers that are not accepted are notified promptly.
- All submitted manuscripts are treated as confidential documents. We expect our Board of Reviewing Editors and reviewers to treat manuscripts as confidential material as well.
- Editors and reviewers involved in the review process should disclose conflicts of interest resulting from direct competitive, collaborative, or other relationships with any of the authors, and remove oneself from cases in which such conflicts preclude an objective evaluation
- Our peer review process is confidential and identities of reviewers cannot be revealed.
Expected time from reception of article to publication in JOAPR is 1-2 weeks. The expected time depends on the the time taken by Reviewer to review the manuscript and the author to comply to the comments of Reviewer.
The authors may contact us for any clarification in our policy
Publication ethics and publication malpractice statement of Journal of Applied Pharmaceutical Research (JOAPR) is mainly based on the Code of Conduct and Best-Practice Guidelines for Journal Editors (Committee on Publication Ethics, 2011).
The editor is responsible for deciding which of the papers submitted to the journal will be published. The editor will evaluate manuscripts without regard to the authors' race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy. The decision will be based on the paper’s importance, originality and clarity, and the study’s validity and its relevance to the journal's scope. Current legal requirements regarding libel, copyright infringement, and plagiarism should also be considered.
The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
Disclosure and conflicts of interest
Unpublished materials disclosed in a submitted paper will not be used by the editor or the members of the editorial board for their own research purposes without the author's explicit written consent.
Contribution to editorial decisions
The peer-reviewing process assists the editor and the editorial board in making editorial decisions and may also serve the author in improving the paper
Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and withdraw from the review process.
Any manuscripts received for review must be treated as confidential documents. They must not be disclosed to or discussed with others except as authorized by the editor.
Standards of objectivity
Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.
Reviewers should identify cases in which relevant published work referred to in the paper has not been cited in the reference section. They should point out whether observations or arguments derived from other publications are accompanied by the respective source. Reviewers will notify the editor of any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
Disclosure and conflict of interest
Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions associated with the papers.
Authors of original research reports should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.
Originality, plagiarism and acknowledgement of sources
Authors will submit only entirely original works, and will appropriately cite or quote the work and/or words of others. Publications that have been influential in determining the nature of the reported work should also be cited.
Multiple, redundant or concurrent publication
In general, papers describing essentially the same research should not be published in more than one journal. Submitting the same paper to more than one journal constitutes unethical publishing behavior and is unacceptable.
Manuscripts which have been published as copyrighted material elsewhere cannot be submitted. In addition, manuscripts under review by the journal should not be resubmitted to copyrighted publications. However, by submitting a manuscript, the author(s) retain the rights to the published material.
Authors and co – authors of the paper
Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors.
The corresponding author ensures that all contributing co-authors and no uninvolved persons are included in the author list. The corresponding author will also verify that all co-authors have approved the final version of the paper and have agreed to its submission for publication.
Disclosure and conflicts of interest
All authors should include a statement disclosing any financial or other substantive conflicts of interest that may be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.
Fundamental errors in published works
When an author discovers a significant error or inaccuracy in his/her own published work, it is the author’s obligation to promptly notify the journal editor or publisher and to cooperate with the editor to retract or correct the paper in form of an erratum.
In submitting an article to Journal of Applied Pharmaceutical Research (JOAPR) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- The article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- The article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.
"Plagiarism is the use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission, and presenting them as new and original rather than derived from an existing source. The intent and effect of plagiarism is to mislead the reader as to the contributions of the plagiarizer. This applies whether the ideas or words are taken from abstracts, research grant applications, Institutional Review Board applications, or unpublished or published manuscripts in any publication format. Plagiarism is scientific misconduct and should be addressed as such.
Self-plagiarism refers to the practice of an author using portions of their previous writings on the same topic in another of their publications, without specifically citing it formally in quotes. This practice is widespread and sometimes unintentional, as there are only so many ways to say the same thing on many occasions, particularly when writing the methods section of an article. Although this usually violates the copyright that has been assigned to the publisher, there is no consensus as to whether this is a form of scientific misconduct, or how many of one's own words one can sue before it is truly "plagiarism." Probably for this reason self-plagiarism is not regarded in the same light as plagiarism of ideas and words of other individuals. If journals have developed a policy on this matter, it should be clearly stated for authors."
Direct plagiarism is the plagiarism of the text. Mosaic plagiarism is the borrowing of ideas and opinions from an original source and a few verbatim words or phrases without crediting the author.
Authors can adhere to the following steps to report plagiarism:
- Inform the editor of the journal where a plagiarized article is published.
- Send original and plagiarized articles with plagiarized part highlighted.
- If evidence of plagiarism is convincing, editor should arrange for a disciplinary meeting.
- Editor of the journal where the plagiarized article should communicate with the editor of the journal containing the original article to rectify the matter.
- The plagiarist should be asked to provide an explanation.
- In case of non response in the stipulated time or an unsatisfactory explanation, the article should be permanently retracted.
- Author should be blacklisted and debarred for submitted an article to a particular journal for at least 6 months.
- The concerned head of the institution has to be notified.
POLICIES ON CONFLICT OF INTEREST, HUMAN RIGHTS, ANIMAL RIGHTS
Human and animal rights
All Researcher must have carry out research within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s)’ institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript with proper justification. Further information and documentation to support this should be made available to Editors on request. Manuscripts may be rejected if the Editor considers that the research has not been carried out within an appropriate ethical framework. In rare cases, Editors may contact the ethics committee for further information.
If a study has not been submitted to an ethics committee prior to commencing, retrospective ethics approval usually cannot be obtained and it may not be possible to consider the manuscript for peer review. How to proceed in such cases is at the Editor(s)’ discretion.
Authors reporting the use of a new procedure or tool in a clinical setting, for example as a technical advance or case report, must give a clear justification in the manuscript for why the new procedure or tool was deemed more appropriate than usual clinical practice to meet the patient’s clinical need. Such justification is not required if the new procedure is already approved for clinical use at the authors’ institution. Authors will be expected to have obtained ethics committee approval and informed patient consent for any experimental use of a novel procedure or tool where a clear clinical advantage based on clinical need was not apparent before treatment.
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript.
For all manuscripts that include details, images, or videos relating to individual participants, written informed consent for the publication of these must be obtained from the participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. If the participant has died, then consent for publication must be sought from the next of kin of the participant. This documentation must be made available to Editors on request, and will be treated confidentially. In cases where images are entirely unidentifiable and there are no details on individuals reported within the manuscript, consent for publication of images may not be required. The final decision on whether consent to publish is required lies with the Editor.
A statement detailing compliance with relevant guidelines and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption and the reasons for the exemption). The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
In order to offer the best possible service to users, the website may automatically collect certain information from your web browser regarding your use of the site. The information will be recorded in web server log files. We may use the information to help us understand more about how our web site is used, to recognize patterns of usage of the site, to improve our site. While we may track site usage, we in no way relate this usage to any users in particular.
Registration on JOAPR website is mandatory for submission of manuscript, review of submitted manuscript by Reviewer. However, registration is not at all required for viewing its content or simply reading the published article. During registration we collect some personal information such as your name, email address, affiliation, research interests, among others. This information enables us to develop and customize products to better meet your needs and preferences. We may contact registered users from time to time to draw your attention to information that may be of interest to you. You may opt out from receiving such email when at any time by contacting our customer service.
Collection of users information for commercial use is strictly not permitted. We will not sell or share any personal information to any third parties without the explicit consent of the user. We endeavor to keep your personal information confidential and protected against unauthorized access through the use of appropriate safeguards.
We reserves the right to disclose any information if we are required to do so by law or to comply with legal process, if we believe it is necessary to take action regarding illegal activities or to protect our rights, or if JOAPR is acquired by, transferred to or merged with another company.
We reserve the right to change this policy at any time without notice. Any changes to this policy will be posted on this web page.
Journal of Applied Pharmaceutical Research (JOAPR) accepts advertising on its official website, http:www.japtronline.com. JOAPR neither endorse advertised company or product, nor is advertising allowed to affect editorial decisions or editorial content.
JOAPR reserves the right to refuse any advertisement that is incompatible with our mission. JOAPR will adhere to all ethical and commonly accepted advertising practices and will ensure that its practices conform to its Vision & Mission. The following types of advertisements are prohibited
- Political and religious advertisements
- Advertisements that claim to offer a miracle cure or method
- Advertisements for alcohol, tobacco or any related product(s)
- Advertisements for weapons, firearms, ammunition and fireworks
- Advertisements for pornography and related materials and services
- Advertisements that make unsubstantiated health claims for the products advertised
- Advertisements will always be allowed only after approval of JOAPR/
- Advertisements, advertising icons and advertiser logos must be clearly distinguishable from editorial content.
- Advertisers may be required to submit supporting documentation to substantiate claims.
- Advertisements may not imply endorsement by the JOAPR
- Neither advertisers nor their agents may collect any personal information from any user viewing JOAPR website except with the user’s knowledge and permission and only after giving the user substantive information about the uses to which the information will be put.
Advertising revenue is used to support the Authors who have limited funds to pay Article Processing Charges (APC).
For questions about online advertising on the JOAPR, contact sales team at +917987014131 or firstname.lastname@example.org
WAIVER OF ARTICLE PROCESSING CHARGE (APC)
The publication of papers submitted to Journal of Applied Pharmaceutical Research (JAPTRonline) incurs an article processing fee (APC) of Rs. 1500 (INR) for Indian Authors & $30 (US Dollar) for Foreign Authors. Authors from SAARC countries can pay in Indian Currency.
Journal for Applied Pharmaceutical Research (JAPTRonline) do not want fees to prevent the publication of worthy work. JAPTRonline also maintains a fund to waive the fee for authors in developing parts of the world whose university or institute is unable to pay, or who have not received sufficient financial support from funding agencies.
We offer a complete or partial/full fee waiver on a case-by-case basis for individual authors or author groups from countries in the developing world, but only if the request for a waiver has been sent to email@example.com after submission of the manuscript.
The corresponding author must send the following information in the letter of request, together with any supporting documents:
- Manuscript title
- Names and titles of all authors
- Institutional affiliations of all authors
- Type of waiver requested: Partial (indicate the amount you can pay in INR/USD) or Full
- Reason for waiver application
Applications that do not contain this information will not be evaluated. The decision of Board member will be informed to author. The decision of Editor – in – Chief will be final and cannot be challenged